BnoX™ - for moderate to severe pain

In August 2016, iX Biopharma announced that it had completed pre-clinical development for BnoX™, a sublingual buprenorphine wafer for moderate to severe pain management.

Buprenorphine is known for its poor bioavailability (reported to be 10% or less) when ingested orally. However, by utilising iX Biopharma’s proprietary sublingual technology WaferiX™, the bioavailability of buprenorphine is expected to be improved multi-fold and result in greater analgesic effect. Sublingual delivery will potentially offer less variability in drug absorption, a more predictable dose and analgesic response to buprenorphine.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com